EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced it will release its first quarter 2008 financial results, for the quarter ended September 30, 2007, and host a conference call on November 8, 2007.
Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Craig W. Carlson, Vice President and Chief Financial Officer. The details for the call are as follows:
http://investor.shareholder.com/ntii/events.cfm
About Neurobiological Technologies, Inc.
NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.
CONTACT: Craig Carlson, CFO of Neurobiological Technologies, Inc.,
+1-510-595-6000
Web site: http://www.ntii.com/
